- Home
- GOSS vs EDD Comparison
GOSS vs EDD Comparison
Compare GOSS & EDD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOSS
- EDD
- Stock Information
- Founded
- GOSS 2015
- EDD 2007
- Country
- GOSS United States
- EDD United States
- Employees
- GOSS N/A
- EDD N/A
- Industry
- GOSS Biotechnology: Pharmaceutical Preparations
- EDD Finance Companies
- Sector
- GOSS Health Care
- EDD Finance
- Exchange
- GOSS Nasdaq
- EDD Nasdaq
- Market Cap
- GOSS 347.8M
- EDD 329.4M
- IPO Year
- GOSS 2019
- EDD N/A
- Fundamental
- Price
- GOSS $2.47
- EDD $5.30
- Analyst Decision
- GOSS Strong Buy
- EDD
- Analyst Count
- GOSS 4
- EDD 0
- Target Price
- GOSS $8.50
- EDD N/A
- AVG Volume (30 Days)
- GOSS 3.1M
- EDD 254.3K
- Earning Date
- GOSS 08-05-2025
- EDD 01-01-0001
- Dividend Yield
- GOSS N/A
- EDD 7.52%
- EPS Growth
- GOSS N/A
- EDD N/A
- EPS
- GOSS N/A
- EDD N/A
- Revenue
- GOSS $40,237,000.00
- EDD N/A
- Revenue This Year
- GOSS N/A
- EDD N/A
- Revenue Next Year
- GOSS $30.65
- EDD N/A
- P/E Ratio
- GOSS N/A
- EDD N/A
- Revenue Growth
- GOSS N/A
- EDD N/A
- 52 Week Low
- GOSS $0.66
- EDD $4.22
- 52 Week High
- GOSS $2.65
- EDD $4.95
- Technical
- Relative Strength Index (RSI)
- GOSS 68.08
- EDD 56.10
- Support Level
- GOSS $2.38
- EDD $5.24
- Resistance Level
- GOSS $2.65
- EDD $5.42
- Average True Range (ATR)
- GOSS 0.15
- EDD 0.05
- MACD
- GOSS 0.03
- EDD -0.01
- Stochastic Oscillator
- GOSS 76.67
- EDD 40.00
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
About EDD Morgan Stanley Emerging Markets Domestic Debt Fund Inc.
Morgan Stanley Emerging Markets Domestic Debt Fund Inc is a closed-end management investment company. The company's primary investment objective is to seek a high level of current income, with a secondary investment objective of long-term capital appreciation. It seeks to achieve investment objectives by investing, under normal circumstances, at least 80% of its managed assets in emerging markets domestic debt. The fund's portfolio includes sovereign, quasi-sovereign, corporate bonds in emerging markets.